Advanced gastric cancer: Current treatment landscape and future perspectives

Table 1 Novel targets are investigation

Name of trial	Regimen		No. of patients	Primary endpoint	NCT number	Country
GO2 - Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer	Best supportive care: Participants will be treated according to local policy. OxCap 100%: oxaliplatin 130 mg/m2 on day 1, capecitabine 625 mg/m2 twice-daily for 21 d.OxCap 80%: oxaliplatin 104 mg/m2 on day 1, capecitabine 500 mg/m2 twice-daily for 21 d. OxCap 60%: oxaliplatin 78 mg/m2 on day 1, capecitabine 375 mg/m2 twice-daily for 21 d.	http://www.isrctn.com/ISRCTN44687907?q=gastric cancer phase III&filters=&sort=&offset=4&totalResults=29&page=1&pageSize=10&searchType=basic-search	530	Chemotherapy intensity comparison:Progression-free survival Chemotherapy vs best supportive care comparison: Overall survival		United Kingdom
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer	Olaparib 100 mg tablets orally twice-daily throughout each cycle (28 d); once paclitaxel dosing is stopped, the olaparib dose will be 300 mg twice-daily.Paclitaxel 80 mg/m2iv infusion over 1 h on days 1, 8 and 15 of a 28-d cycle.	https://http://www.clinicaltrials.gov/show/nct01924533	500	Overall survival	NCT01924533	China, South Korea, Japan, Taiwan
HELOISE - A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer	Capecitabine 1600 mg/m2 orally daily on days 1-14 of each 3-wk cycle (6 cycles)Cisplatin 80 mg/m2iv on day 1 of each 3-wk cycle (6 cycles). Trastuzumab (Herceptin) 8 mg/kg iv loading dose, followed by 6 mg/kg iv every 3 wk.	https://http://www.clinicaltrials.gov/show/nct01450696	400	Overall survival	NCT01450696	25 countries worldwide
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer	Standard taxane (docetaxel or paclitaxel) according to investigator choice. Trastuzumab emtansine 3.6 mg/kg or 2.4 mg/kg once- wk every 3 wk.	https://http://www.clinicaltrials.gov/show/nct01641939	412	Overall survival	NCT01641939	30 countries worldwide
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer (EGFR + IHC)	Irinotecan 150 mg/m2iv once every 2 wk until progression or unacceptable toxicity develops, with or without nimotuzumab 400 mg iv once-wk until progression or unacceptable toxicity develops.	https://clinicaltrials.gov/ct2/show/NCT01813253	400	Overall Survival	NCT01813253	Japan, South Korea
RAINFALL - A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Cisplatin 80 mg/m2iv on day 1 of each 21-d cycle (for up to 6 cycles) and 1000 mg/m2 capecitabine orally twice-daily on days 1-14 with or without ramucirumab 8 mg/kg iv on days 1 and 8	https://clinicaltrials.gov/ct2/show/NCT02314117?term=Ramucirumab+gastric&rank=5	616	Progression-free survival	NCT02314117	20 countries worldwide
AIO-STO-0111 - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy	Paclitaxel 80 mg/m2 on days 1, 8 and 15 of every 28-d cycle with or without everolimous 10 mg (2 × 5 mg tablets) per day on days 1-28	https://clinicaltrials.gov/ct2/show/NCT01248403	480	Overall survival	NCT01248403	Germany
BRIGHTER - A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Paclitaxel 80 mg/m2iv infusion on days 1, 8 and 15 of every 4-wk cycle with or without BBI608 480 mg orally twice-daily	https://clinicaltrials.gov/ct2/show/NCT02178956?term=BBI608+GASTRIC&rank=1	680	Overall survival	NCT02178956	United States